A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
Аутори
Vekić, JelenaZeljković, Aleksandra
Rasadi, Khalid
Cesur, Mustafa
Silva-Nunes, José
Pantea Stoian, Anca
Rizzo, Manfredi
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atheroge...nic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.
Кључне речи:
Cardiovascular risk / Lipoproteins / Diabetes / Atherosclerosis / Small dense LDL / GLP-1 / Incretins / TherapyИзвор:
Metabolites, 2022, 12, 2Издавач:
- MDPI
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200161 (Универзитет у Београду, Фармацеутски факултет) (RS-MESTD-inst-2020-200161)
DOI: 10.3390/metabo12020108
ISSN: 2218-1989
WoS: 000769695200001
Scopus: 2-s2.0-85124146362
Институција/група
PharmacyTY - JOUR AU - Vekić, Jelena AU - Zeljković, Aleksandra AU - Rasadi, Khalid AU - Cesur, Mustafa AU - Silva-Nunes, José AU - Pantea Stoian, Anca AU - Rizzo, Manfredi PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4054 AB - The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk. PB - MDPI T2 - Metabolites T1 - A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies VL - 12 IS - 2 DO - 10.3390/metabo12020108 ER -
@article{ author = "Vekić, Jelena and Zeljković, Aleksandra and Rasadi, Khalid and Cesur, Mustafa and Silva-Nunes, José and Pantea Stoian, Anca and Rizzo, Manfredi", year = "2022", abstract = "The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.", publisher = "MDPI", journal = "Metabolites", title = "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies", volume = "12", number = "2", doi = "10.3390/metabo12020108" }
Vekić, J., Zeljković, A., Rasadi, K., Cesur, M., Silva-Nunes, J., Pantea Stoian, A.,& Rizzo, M.. (2022). A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites MDPI., 12(2). https://doi.org/10.3390/metabo12020108
Vekić J, Zeljković A, Rasadi K, Cesur M, Silva-Nunes J, Pantea Stoian A, Rizzo M. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites. 2022;12(2). doi:10.3390/metabo12020108 .
Vekić, Jelena, Zeljković, Aleksandra, Rasadi, Khalid, Cesur, Mustafa, Silva-Nunes, José, Pantea Stoian, Anca, Rizzo, Manfredi, "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies" in Metabolites, 12, no. 2 (2022), https://doi.org/10.3390/metabo12020108 . .